Intraoperative Radiation Therapy for Pancreatic Cancer

This study is looking at a treatment called Intraoperative Radiation Therapy (IORT) for people with pancreatic cancer that can be removed by surgery. You would first receive standard chemotherapy and Stereotactic Body Radiation Therapy (SBRT). Then, during surgery to remove the tumor, you would receive a single dose of radiation (15 Gy) directly to the area where the tumor was. Doctors want to see how safe this treatment is by checking for any side effects within three months after surgery. This study is for adults over 18 with certain types of pancreatic cancer and good general health. The study plans to enroll 25 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It is designed to enroll 25 participants.
What's involved
You would receive standard chemotherapy and SBRT, followed by surgery where you would also receive a single dose of IORT. Your health would be monitored for three months after surgery.
Compensation
Not stated in the trial record.
Follow-up
Your acute post-operative toxicity will be measured at 3 months after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05141513

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
~20 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acute post-operative toxicity of targeted IORT
Measured over 3 months
Pancreatic Cancer
1 sites across 1 states
Maryland1
  • Amol Narang, MD · PRINCIPAL_INVESTIGATOR · JHU, School of Medicine, SKCCC

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Acute post-operative toxicity of targeted IORT3 months

    To evaluate acute post-operative toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT.